Table 1.

Presenting clinical and laboratory characteristics.

CharacteristicsPositiveIsolated TSVINegative
No. patients101310
Age, mean ± SEM yrs70 ± 2.975 ± 2.076 ± 3.2
Female:male6:48:510:0
Headache, % (n)70 (7)54 (7)90 (9)
Scalp tenderness, % (n)30 (3)23 (3)20 (2)
Temporal artery abnormality, % (n)70 (7)39 (5)40 (4)
PMR*, % (n)30 (3)77 (10)50 (5)
Jaw claudication, % (n)40 (4)15 (2)30 (3)
Any visual symptom, % (n)10 (1)38 (5)50 (5)
Diplopia, % (n)0010 (1)
Blurred vision, % (n)10 (1)23 (3)30 (3)
Diminished visual acuity, % (n)015 (2)10 (1)
Fever, % (n)40 (4)23 (3)0
Weight loss, % (n)20 (2)31 (4)20 (2)
ESR, mm/b, mean ± SEM**92 ± 9.787 ± 6.662 ± 9.4
Hemoglobin, g/dl, mean ± SEM11.8 ± 0.312.0 ± 0.612.5 ± 0.6
  • * Isolated TSVI vs positive, p = 0.040.

  • ** Isolated TSVI vs negative, p = 0.026; positive vs negative, p = 0.029.

  • Hemoglobin was not reported in 1 from the negative group prior to initiating corticosteroid therapy and was not calculated in the mean hemoglobin. TSVI: temporal small-vessel inflammation; PMR: polymyalgia rheumatica; ESR: erythrocyte sedimentation rate.